RCS - Verici Dx PLC - Commercial Team Appointments

Verici DxAnnouncement

09/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220609:nRSI2422Oa&default-theme=true

RNS Number : 2422O  Verici Dx PLC  09 June 2022

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Commercial Team Appointments

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces the senior appointments of Grant Harvey and Dr.
Windy Tucci as Business Development Director and Medical Science Liaison
Director, respectively, with immediate effect.

 

Grant and Windy join the Verici Dx commercial team ahead of the planned
commercial launch of Tuteva™, a post-transplant test focused upon acute
cellular rejection, including sub-clinical rejection, which is expected to
commence in the latter part of 2022.

 

Grant Harvey, Business Development Director

 

Grant joined Verici Dx in June 2022 and brings more than 20 years of cross
functional expertise in business development, sales leadership, marketing and
training, as well as talent acquisition with a career portfolio of
pharmaceuticals, medical services, and diagnostic products.

 

Prior to partnering with the Verci Dx team, Grant served as a Senior GI
Specialty Manager for Exact Sciences, a molecular diagnostics company
specializing in the detection of early-stage cancers. Before joining Exact
Sciences, Grant served as the Southeast Regional Director with USWorldmeds in
the Parkinson's Disease space.

 

Grant also held numerous senior leadership roles with Horizon Therapeutics, a
biopharmaceutical company focused on researching, developing and
commercializing medicines that address critical needs for people impacted by
rare and rheumatic diseases. He also led national sales teams and key account
managers in results-driven collaboration.

 

As director of business development with Fresenius Medical, a German
healthcare company which provides kidney dialysis services, he worked with
nephrology practices and health systems to overcome marketplace challenges and
capitalize on opportunities to improve outcomes and services for dialysis
patients.

 

Grant received his MBA from Elon University and his BS in Marketing from the
University of North Carolina Wilmington.

 

Dr. Windy Tucci, Medical Science Liaison Director

 

Dr. Windy M. Tucci joined Verici Dx earlier in 2022 with over 15 years of
'hands on' clinical patient care and Pharmaceutical Industry experience in
therapeutic areas focusing on Transplant, Gastroenterology, Oncology,
Neurology, Cardiology and Nephrology.

 

She achieved her Doctorate in Pharmacy from the University of Florida, having
previously graduated from Roger Williams University.

 

Prior to Joining Verici Dx, she was the Clinical Lead for the south with
Otsuka America Pharmaceutical, and led the Medical Science Liaison team with
Exact Sciences where she worked directly with Health Systems, Large Specialty
Practices, Healthcare Providers and professional organizations. In these
roles, Windy was instrumental in developing new approaches to expand business
opportunities, implement sales team expansion and new collaborations, and
support pipeline clinical research initiatives.

 

Sara Barrington, CEO, Verici Dx, said: "We are delighted to welcome Grant and
Windy to Verici's commercial team. They bring 35 years of combined industry
experience, which will be of great benefit to our team as we launch Tuteva™
commercially later this year."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Kailey Aliyar / Rachel Hayes

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKFBBBBKBBAK